Newsroom
Strive to Deliver Breakthroughs
Harbour BioMed reels in $75M as proprietary pipeline hits clinic
View moreBiotech lures foreign investors, signs COVID-19 partnership
View moreHarbour BioMed Tacks on $75M to Advance Broad Biologics Pipeline
View moreHarbour, Mount Sinai partner to develop Mabs targeting cancer, immunology and coronavirus
View moreHarbour BioMed and PPD Form Strategic Collaboration to Develop Innovative Therapeutics for Oncology and Immunology
View moreJingsong Wang – CEO, Harbour BioMed, China
View morePharma Valley, China’s equivalent of Kendall Square, is expanding rapidly
View moreSingapore’s GIC leads $85m Series B round for China’s Harbour BioMed
View moreChinese biotech Harbour lands $85M to run cancer trials
View moreHarbour BioMed follows cancer drug deals with a hefty $85M Series B backed by Singapore’s GIC
View more